Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

jective response rate. This global study, conducted by Janssen, was opened in Q1 of 2013 and Janssen plans to enroll 110 patients.

Conference Call and further Corporate UpdatesThe Company will hold a conference call today at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. To access a replay of the call please dial 1-877-660-6853 domestic callers and 1-201-612-7415 for international callers and use the conference ID number: 413317.  The archived version of the webcast and conference call will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

About IbrutinibIbrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, cell adhesion, and cell migration and homing.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenström's macroglobulinemia and multiple myeloma. To date 5 Phase III trials have been initiated with ibrutinib and a total of 28 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Hospira Reports First-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
(Date:8/21/2014)... InfinityQS International, Inc., the global authority ... today announces Infusion Chicago, its 9 th ... Oct. 9-10, 2014, at the Chicago Marriott Downtown ... necessity for implementing a quality system that optimizes ... gain insight into production processes. Complimentary registrations are ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
... CITY, Nev., Nov. 22, 2011   Denali Concrete Management ... November 21, 2011 of the reverse acquisition of Denali ... of which Denali acquired all the outstanding shares of ... has been granted from Can-Fite an exclusive license over ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... in treating respiratory syncytial virus (RSV), a leading cause of ... major progress in being able to treat human RSV infections ... second only to influenza virus," said study author Dr. John ... College of Medicine in Memphis. "There is no ...
(Date:8/21/2014)... According to the new report “Waterborne Coatings ... PTFE, PVDF, PVDC, & Others), by Application (Architectural, ... & Others) - Global Forecast to 2019” published ... estimated to reach $77,838.71 Million by 2019. , ... spread through 225 Slides and in-depth TOC on ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... "Enteral Feeding Devices Market (Enteral Feeding Tubes, Enteral Feeding ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 ... valued at USD 2.0 billion in 2012 and is ... billion in 2019growing at a CAGR of 6.2% from ...
(Date:8/21/2014)... polio is considered nearly eradicated. Each year only a ... the University of Bonn, together with colleagues from Gabon, ... able to resist the vaccine protection to a considerable ... the Congo in 2010. The pathogen could also potentially ... now in the magazine PNAS . , The ...
(Date:8/21/2014)... One of the emerging trends that the Intranasal ... increasing adoption of non-invasive administration products. As non-invasive nasal ... their convenient application, they find more preference among end-users. ... used for the administration of drugs for the treatment ... such as allergic and non-allergic rhinitis and sinusitis. The ...
Breaking Medicine News(10 mins):Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5
... 24 NHS Choices ( http://www.nhs.uk ), the,digital ... well guide on women,s,health aged 18-39 aimed at ... lifestyle., Based on NHS accredited information, the ... with information about,walking to get healthy, looking after ...
... June 24 TransUnion announced today a ... cycle workflow and,financial analytics product suite -- ... Institute (ANI) Healthcare Financing Conference. Revenue,Manager is ... real time,patient eligibility for financial assistance at ...
... LOS ANGELES, June 24 Anti-Doping Research,Inc. (ADR), one ... performance-enhancing drugs in sport, is pleased to announce that ... "We,ve been up and running and fully-operational for a ... Officer of the organization. "But,now it,s all official and ...
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical ... today, in an update for Company,shareholders, said its ... 31, 2008,totaled $32,300., Net income for the ... Company announced that patient billings from its four ...
... To, Implement Electronic Bill / Payment Solutions Before Minnesota,s ... ... and CONCORD, Calif., June 24 More than one,hundred auto insurance ... Mitchell Medical,s 2008 Industry,Conference held March 17-19 in Monterey, CA were ...
... in Generic Market Information Offers Newport Horizon ... ... SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the,world,s leading ... CPhI China 2008(1) the release of Newport,Horizon Premium, designed specifically ...
Cached Medicine News:Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 2Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 3Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 4Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 3Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 4Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 2Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: